Synopsis:
Penn Surgery chief resident Dr. Sharon and colleagues conducted a follow-up study of a previously published phase Ib clinical trial evaluating the long-term outcomes of patients with resectable stage III/IV cutaneous melanoma who received a single dose of neoadjuvant pembrolizumab 3 weeks before surgical resection followed by 1 year of adjuvant pembrolizumab. This study demonstrated the long-term efficacy of single-agent neoadjuvant/adjuvant PD-1 blockade in patients with major pathologic response (MPR).
Summary:
For patients with resectable III/IV cutaneous melanoma, standard treatment consists of upfront surgery with consideration for adjuvant treatment. Recently, the use of neoadjuvant targeted and immune therapies has gained interest in recent years. A phase IB clinical trial published by Huang et al. evaluated a single dose of neoadjuvant pembrolizumab in addition to 1 year of adjuvant pembrolizumab for 30 patients with resectable stage III/IV cutaneous melanoma and found a 2-year disease free survival of 100% in those with MPR. However, there is a significant lack of data around long term follow up for patients who have received neoadjuvant immunotherapy.
The present study published 5-year follow-up results from the Huang et al. trial which represents the longest follow-up of single-agent neoadjuvant PD-1 blockade. Thirty patients were included in the analysis with a median follow-up of 61.9 months. No deaths occurred in patients with MPR or complete pathologic response (pCR) (n=8) compared to the remainder of the cohort (72.8% 5-year overall survival, p=0.12). 5-year disease-free survival was 75.0% for patients with MPR compared to 63.6% in the remainder of the cohort (p=0.41).
A total of 10 patients in the cohort developed a recurrence. Of those with recurrence 8 of 22 (36%) were from pathologic non-responders (pNR) and 2 of 10 (20%) from patients with MPR. There were no recurrences in the pCR group. Median time to recurrence in the MPR group was 3.9 years compared to a median of 0.6 years in the patients with >10% viable tumor (P=0.04). Additionally, patients with MPR who develop recurrences appear to be responsive to subsequent treatment without any resulting in deaths after 5 years of follow-up.
This study has some limitations that should be considered. First, the data were generated from a phase Ib trial, which limits the statistical power to detect significant differences due to the small sample size. Additionally, this study lacked the comparison group of adjuvant therapy without the use of neoadjuvant pembrolizumab. Despite these limitations, the study was one of the first to provide long term follow up for patients with melanoma after receiving one dose of neoadjuvant pembrolizumab.
Bottom Line:
This study highlights the long-term efficacy of single-agent neoadjuvant/adjuvant PD-1 blockade in patients with resectable stage III/IV cutaneous melanoma and highlights the importance of long-term follow-up for these patients. Response to neoadjuvant therapy remains an important prognosticator.